B7-H3 silencing by RNAi inhibits tumor progression and enhances chemosensitivity in U937 cells

OncoTargets and Therapy

Volumn 8, Issue , 2015, Pages 1721-1733

  Zhang, Wei ^a   Wang, Jing ^a   Wang, Yanfang ^a   Dong, Fei ^a   Zhu, Mingxia ^a   Wan, Wenli ^a   Li, Haishen ^a   Wu, Feifei ^a   Yan, Xinxing ^a   Ke, Xiaoyan ^a  

^a PEKING UNIVERSITY THIRD HOSPITAL   (China)

Author keywords

Acute monocytic leukemia; B7 H3; Cancer gene therapy; Chemosensitivity

Indexed keywords

B7 H3 PROTEIN; CYCLINE; CYTARABINE; IDARUBICIN; KI 67 ANTIGEN; LENTIVIRUS VECTOR; LYMPHOCYTE ANTIGEN; SHORT HAIRPIN RNA; UNCLASSIFIED DRUG;

ACUTE MONOCYTIC LEUKEMIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; B7 H3 GENE; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CARCINOGENICITY; CELL COUNTING; CHEMOSENSITIVITY; COLONY FORMING UNIT; CONTROLLED STUDY; DOWN REGULATION; DRUG CYTOTOXICITY; DRUG EFFICACY; FEMALE; G1 PHASE CELL CYCLE CHECKPOINT; GENE; GENE SILENCING; GENETIC TRANSDUCTION; HUMAN; HUMAN CELL; IN VITRO GENE TRANSFER; IN VIVO STUDY; MIGRATION INHIBITION; MONOTHERAPY; MOUSE; NONHUMAN; OUTCOME ASSESSMENT; PROTEIN EXPRESSION; RNA INTERFERENCE; TUMOR VOLUME; TUMOR XENOGRAFT; U937 CELL LINE; VIRAL GENE DELIVERY SYSTEM;

EID: 84937706388     PISSN: None     EISSN: 11786930     Source Type: Journal    
DOI: 10.2147/OTT.S85272     Document Type: Article

References (37)

1. Yu H, Li Y, Gao C, et al. Relevant mouse model for human monocytic leukemia through Cre/lox-controlled myeloid-specific deletion of PTEN. Leukemia. 2010;24(5):1077–1080.
2. Tallman MS, Kim HT, Paietta E, et al; Eastern Cooperative Oncology Group. Acute monocytic leukemia (French-American-British classification M5) does not have a worse prognosis than other subtypes of acute myeloid leukemia: a report from the Eastern Cooperative Oncology Group. J Clin Oncol. 2004;22(7):1276–1286.
3. Baer MR, Stewart CC, Lawrence D, et al. Acute myeloid leukemia with 11q23 translocations: myelomonocytic immunophenotype by multiparameter flow cytometry. Leukemia. 1998;12(3):317–325.
4. Chapoval AI, Ni J, Lau JS, et al. B7-H3: a costimulatory molecule for T cell activation and IFN-gamma production. Nat Immunol. 2001;2(3):269–274.
5. Luo L, Chapoval AI, Flies DB, et al. B7-H3 enhances tumor immunity in vivo by costimulating rapid clonal expansion of antigen-specific CD8+ cytolytic T cells. J Immunol. 2004;173(9):5445–5450.
6. Xu H, Cheung IY, Guo HF, Cheung NK. MicroRNA miR-29 modulates expression of immunoinhibitory molecule B7-H3: potential implications for immune based therapy of human solid tumors. Cancer Res. 2009;69(15):6275–6281.
7. Ingebrigtsen VA, Boye K, Tekle C, Nesland JM, Flatmark K, Fodstad O. B7-H3 expression in colorectal cancer: nuclear localization strongly predicts poor outcome in colon cancer. Int J Cancer. 2012;131(11):2528–2536.
8. Sun TW, Gao Q, Qiu SJ, et al. B7-H3 is expressed in human hepatocellular carcinoma and is associated with tumor aggressiveness and postoperative recurrence. Cancer Immunol Immunother. 2012;61(11):2171–2182.
9. Chen C, Shen Y, Qu QX, Chen XQ, Zhang XG, Huang JA. Induced expression of B7-H3 on the lung cancer cells and macrophages suppresses T-cell mediating anti-tumor immune response. Exp Cell Res. 2013;319(1):96–102.
10. Yamato I, Sho M, Nomi T, et al. Clinical importance of B7-H3 expression in human pancreatic cancer. Br J Cancer. 2009;101(10):1709–1716.
11. Arigami T, Narita N, Mizuno R, et al. B7-h3 ligand expression by primary breast cancer and associated with regional nodal metastasis. Ann Surg. 2010;252(6):1044–1051.
12. Hu Y, Lv X, Wu Y, et al. Expression of costimulatory molecule B7-H3 and its prognostic implications in human acute leukemia. Hematology. 2015;20(4):187–195.
13. Guéry T, Roumier C, Berthon C, et al. The B7-H3 protein in acute myeloid leukemia. Blood. 2013;122(21):2620.
14. Zhao DD, Lin L, Ge Q, et al. [Relation of B7-H3 molecule expression in multiple myeloma with poor prognosis and bone destruction]. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2013;21(3):637–642. Chinese.
15. Sun X, Vale M, Leung E, Kanwar JR, Gupta R, Krissansen GW. Mouse B7-H3 induces antitumor immunity. Gene Ther. 2003;10(20):1728–1734.
16. Suh WK, Gajewska BU, Okada H, et al. The B7 family member B7-H3 preferentially down-regulates T helper type 1-mediated immune responses. Nat Immunol. 2003;4(9):899–906.
17. Leitner J, Klauser C, Pickl WF, et al. B7-H3 is a potent inhibitor of human T-cell activation: No evidence for B7-H3 and TREML2 interaction. Eur J Immunol. 2009;39(7):1754–1764.
18. Brunner A, Hinterholzer S, Riss P, Heinze G, Brustmann H. Immunoexpression of B7-H3 in endometrial cancer: relation to tumor T-cell infiltration and prognosis. Gynecol Oncol. 2012;124(1):105–111.
19. Chen YW, Tekle C, Fodstad O. The immunoregulatory protein human B7H3 is a tumor-associated antigen that regulates tumor cell migration and invasion. Curr Cancer Drug Targets. 2008;8(5):404–413.
20. Zhao X, Li DC, Zhu XG, et al. B7-H3 overexpression in pancreatic cancer promotes tumor progression. Int J Mol Med. 2013;31(2):283–291.
21. Yuan H, Wei X, Zhang G, Li C, Zhang X, Hou J. B7-H3 over expression in prostate cancer promotes tumor cell progression. J Urol. 2011;186(3):1093–1099.
22. Lemke D, Pfenning PN, Sahm F, et al. Costimulatory protein 4IgB7H3 drives the malignant phenotype of glioblastoma by mediating immune escape and invasiveness. Clin Cancer Res. 2012;18(1):105–117.
23. Tekle C, Nygren MK, Chen YW, et al. B7-H3 contributes to the metastatic capacity of melanoma cells by modulation of known metastasis-associated genes. Int J Cancer. 2012;130(10):2282–2290.
24. Wang J, Chong KK, Nakamura Y, et al. B7-H3 associated with tumor progression and epigenetic regulatory activity in cutaneous melanoma. J Invest Dermatol. 2013;133(8):2050–2058.
25. Wang L, Zhang Q, Chen W, et al. B7-H3 is overexpressed in patients suffering osteosarcoma and associated with tumor aggressiveness and metastasis. PLoS One. 2013;8(8):e70689.
26. Li Y, Wang J, Li C, Ke XY. Contribution of PD-L1 to oncogenesis of lymphoma and its RNAi-based targeting therapy. Leuk Lymphoma. 2012;53(10):2015–2023.
27. Zhang W, Wang Y, Wang J, et al. B7-H3 silencing inhibits tumor progression of mantle cell lymphoma and enhances chemosensitivity. Int J Oncol. 2015;46(6):2562–2572.
28. Liu H, Tekle C, Chen YW, et al. B7-H3 silencing increases paclitaxel sensitivity by abrogating Jak2/Stat3 phosphorylation. Mol Cancer Ther. 2011;10(6):960–971.
29. Sun Y, Wang Y, Zhao J, et al. B7-H3 and B7-H4 expression in non-small-cell lung cancer. Lung Cancer. 2006;53(2):143–151.
30. Shapiro SD. Matrix metalloproteinase degradation of extracellular matrix: biological consequences. Curr Opin Cell Biol. 1998;10(5):602–608.
31. Liu FT, Kelsey SM, Newland AC, Jia L. Generation of reactive oxygen species is not involved in idarubicin-induced apoptosis in human leukaemic cells. Br J Haematol. 2001;115(4):817–825.
32. Iacobini M, Menichelli A, Palumbo G, Multari G, Werner B, Del Principe D. Involvement of oxygen radicals in cytarabine-induced apoptosis in human polymorphonuclear cells. Biochem Pharmacol. 2001;61(8):1033–1040.
33. Cryns V, Yuan J. Proteases to die for. Genes Dev. 1998;12(11):1551–1570.
34. Thornberry NA, Lazebnik Y. Caspases: enemies within. Science. 1998;281(5381):1312–1316.
35. Zhang T, Jiang B, Zou ST, Liu F, Hua D. Overexpression of B7-H3 augments anti-apoptosis of colorectal cancer cells by Jak2-STAT3. World J Gastroenterol. 2015;21(6):1804–1813.
36. Wang L, Kang FB, Shan BE. B7-H3-mediated tumor immunology: Friend or foe? Int J Cancer. 2014;134(12):2764–2771.
37. Zhao X, Zhang GB, Gan WJ, et al. Silencing of B7-H3 increases gemcitabine sensitivity by promoting apoptosis in pancreatic carcinoma. Oncol Lett. 2013;5(3):805–812.